Abstract
Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance
Highlights
15% of patients with ovarian cancer have a germline BRCA variation,[1] which has important implications, including increased sensitivity to platinum-based chemotherapy and poly(ADP-ribose) polymerase inhibitors and improved survival.[2]
Testing rates increased from 14.7% (55 of 375 patients) in 2008 to 46.4% (96 of 207 patients) in 2018; the median time to testing decreased from 280.0 to 72.5 days (Figure)
In adjusted analyses, testing was lower for older women and women with more comorbidities (Charlson Comorbidity Index score Ն2 vs 0: adjusted difference, −4.6 percentage points; 95% CI, −8.9 to −0.2 percentage points)
Summary
15% of patients with ovarian cancer have a germline BRCA (gBRCA) variation,[1] which has important implications, including increased sensitivity to platinum-based chemotherapy and poly(ADP-ribose) polymerase inhibitors and improved survival.[2]. Testing rates are reportedly between 10% and 30%,4 and few studies have examined commercially insured populations or identified patient-, physician-, and practice-level characteristics associated with testing rates
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
